Ask about FDA oncology approvals, clinical trials, and treatment guidelines. Launch Oncology AI Chat By. Funda Meric-Bernstam, MD Date. 10/11/2023 LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors. Professor Funda Meric-Bernstam presented pivotal findings at the ESMO Congress 2023, shedding light on the latest developments in the realm of cancer treatment. … Continue reading T-DXd HER2 New Insights for Breast Cancer – Funda Meric-Bernstam, MD – ESMO 2023